PMID- 29928387
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 16
IP  - 1
DP  - 2018 Jul
TI  - Naringin inhibits ovarian tumor growth by promoting apoptosis: An in vivo study.
PG  - 59-64
LID - 10.3892/ol.2018.8611 [doi]
AB  - The aim of the present study was to investigate the antitumor activities of 
      naringin in ovarian cancer, and to assess the underlying mechanisms. Ovarian 
      tumor cells were implanted into nude mice to produce ovarian tumors in vivo. The 
      mice were divided into six groups: Control, low dose naringin [0.5 mg/kg, 
      intraperitoneal (i.p.)], middle dose naringin (1 mg/kg, i.p.), high dose naringin 
      (2 mg/kg, i.p.), positive control (cisplatin, 2 mg/kg, i.p.) and a combination of 
      cisplatin and naringin (both 2 mg/kg). Following administration of naringin 
      and/or cisplatin, the tumor size and weight were measured. Apoptosis of tumor 
      cells was detected using a terminal deoxynucleotidyl transferase dUTP nick end 
      labeling assay. Apoptosis-associated gene expression was detected using reverse 
      transcription-polymerase chain reaction and immunohistochemistry. In the range of 
      0.5-2 mg/kg, naringin dose-dependently inhibited tumor growth, as demonstrated by 
      a decrease in tumor size and weight. Naringin promoted apoptosis of the ovarian 
      tumor cells. Additionally, naringin reduced the expression of B-cell lymphoma 
      (Bcl)-2, Bcl-extra large (Bcl-xL), cyclin D1, c-Myc and survivin, while it 
      increased the expression of caspase-3 and caspase-7. The data demonstrated that 
      naringin inhibited ovarian tumor growth in vivo. Its mechanisms may be associated 
      with caspase-7-, caspase-3-, Bcl-2- and Bcl-xL-mediated apoptosis. Nevertheless, 
      the clinical application of naringin in the treatment of ovarian cancer requires 
      further study.
FAU - Cai, Liping
AU  - Cai L
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of 
      Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
FAU - Wu, Heli
AU  - Wu H
AD  - Graduate School, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
FAU - Tu, Chunhua
AU  - Tu C
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of 
      Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
FAU - Wen, Xiaochun
AU  - Wen X
AD  - Graduate School, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
FAU - Zhou, Bei
AU  - Zhou B
AD  - Graduate School, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180502
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6006451
OTO - NOTNLM
OT  - apoptosis
OT  - cyclin D1
OT  - naringin
OT  - ovarian cancer
EDAT- 2018/06/22 06:00
MHDA- 2018/06/22 06:01
PMCR- 2018/05/02
CRDT- 2018/06/22 06:00
PHST- 2017/07/05 00:00 [received]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2018/06/22 06:00 [entrez]
PHST- 2018/06/22 06:00 [pubmed]
PHST- 2018/06/22 06:01 [medline]
PHST- 2018/05/02 00:00 [pmc-release]
AID - OL-0-0-8611 [pii]
AID - 10.3892/ol.2018.8611 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Jul;16(1):59-64. doi: 10.3892/ol.2018.8611. Epub 2018 May 2.